These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32378622)

  • 21. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia.
    Rekhi G; Alphs L; Ang MS; Lee J
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1433-1441. PubMed ID: 31761524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?
    Schennach R; Riedel M; Obermeier M; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ
    Eur Psychiatry; 2015 Jan; 30(1):43-50. PubMed ID: 25541347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Greek version of the calgary depression scale for schizophrenia.
    Kontaxakis VP; Havaki-Kontaxaki BJ; Margariti MM; Stamouli SS; Kollias CT; Angelopoulos EK; Christodoulou GN
    Psychiatry Res; 2000 May; 94(2):163-71. PubMed ID: 10808041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia.
    El Yazaji M; Battas O; Agoub M; Moussaoui D; Gutknecht C; Dalery J; d'Amato T; Saoud M
    Schizophr Res; 2002 Jul; 56(1-2):121-7. PubMed ID: 12084426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale.
    Schennach R; Obermeier M; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M; Möller HJ
    Psychopathology; 2012; 45(5):276-85. PubMed ID: 22796716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scales for assessment of depression in schizophrenia: Factor analysis of calgary depression rating scale and hamilton depression rating scale.
    Grover S; Sahoo S; Dua D; Chakrabarti S; Avasthi A
    Psychiatry Res; 2017 Jun; 252():333-339. PubMed ID: 28315621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of real-world daily-living skills in early-onset schizophrenia trough the Life Skills Profile scale.
    Puig O; Penadés R; Baeza I; De la Serna E; Sánchez-Gistau V; Lázaro L; Bernardo M; Castro-Fornieles J
    Schizophr Res; 2013 Apr; 145(1-3):95-100. PubMed ID: 23384737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of resistance to voices on depression].
    Monestès JL; Vavasseur-Desperriers J; Villatte M; Denizot L; Loas G; Rusinek S
    Encephale; 2015 Feb; 41(1):25-31. PubMed ID: 24815790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia.
    Ichioka S; Terao T; Hoaki N; Matsushita T; Hoaki T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):170-4. PubMed ID: 22750309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between quality of life and clinical factors in inpatients with schizophrenia.
    Ishii Y; Tomotake M; Chiba S; Tsutsumi R; Aono M; Taguchi K
    J Med Invest; 2022; 69(1.2):80-85. PubMed ID: 35466151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive insight, neurocognition and life skills in patients with schizophrenia.
    Simón Expósito M; Felipe-Castaño E
    Psicothema; 2018 Aug; 30(3):251-256. PubMed ID: 30009745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender Differences of Schizophrenia Patients With and Without Depressive Symptoms in Clinical Characteristics.
    Liu R; Fang X; Yu L; Wang D; Wu Z; Guo C; Teng X; Ren J; Zhang C
    Front Psychiatry; 2021; 12():792019. PubMed ID: 35095605
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia.
    Asevedo E; Rizzo LB; Gadelha A; Mansur RB; Ota VK; Berberian AA; Scarpato BS; Teixeira AL; Bressan RA; Brietzke E
    Physiol Behav; 2014 Apr; 129():194-8. PubMed ID: 24576679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive impairments in first-episode drug-naive and chronic medicated schizophrenia: MATRICS consensus cognitive battery in a Chinese Han population.
    Wu JQ; Chen DC; Tan YL; Xiu MH; De Yang F; Soares JC; Zhang XY
    Psychiatry Res; 2016 Apr; 238():196-202. PubMed ID: 27086233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
    Zhou Y; Li G; Li D; Cui H; Ning Y
    J Psychopharmacol; 2018 May; 32(5):524-532. PubMed ID: 29493377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic validity of assessment scales for depression in patients with schizophrenia.
    Kim SW; Kim SJ; Yoon BH; Kim JM; Shin IS; Hwang MY; Yoon JS
    Psychiatry Res; 2006 Sep; 144(1):57-63. PubMed ID: 16904189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition.
    Kanchanatawan B; Thika S; Anderson G; Galecki P; Maes M
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt C):168-176. PubMed ID: 28666826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.